4 min read
Cleerly: February 27, 2023
Quantification of coronary artery disease (CAD) burden and atherosclerotic plaque type has been shown to be the strongest determinant of future risk of major adverse cardiac events (MACE).1 Until recently, though, there had been no clinically useful...
Read More »
3 min read
Cleerly: February 27, 2023
Care quality is a pillar of the Quadruple Aim for a reason. Stakeholders across the healthcare ecosystem benefit when patients have access to the...
4 min read
Cleerly: February 13, 2023
Heart disease is the cause of death for 700,000 Americans1 and nearly 17.9 million people worldwide every year.2 While some of these individuals...
4 min read
Cleerly: January 17, 2023
Current methodologies for coronary artery disease (CAD) screening often result in misidentification of low-risk patients and may submit patients to...
2 min read
Cleerly: January 17, 2023
Cleerly is making the future of cardiovascular care possible through easy-to-use, clinically proven technology that effortlessly integrates into...
3 min read
Cleerly: January 17, 2023
Current methodologies for screening for coronary artery disease (CAD) at the primary care provider’s office are often limited. And once heart disease...
2 min read
Cleerly: January 10, 2023
Cleerly makes early detection of heart disease risk possible through our AI-enabled analysis of coronary computed tomography angiography (CCTA)...
3 min read
Cleerly: November 9, 2022
Cleerly’s Medical Affairs team had the opportunity to present at the American Heart Association’s (AHA) 2022 Scientific Sessions this past week in...
3 min read
Cleerly: October 18, 2022
Half of patients who have a heart attack don't show symptoms prior to their event. A new standard of precision care that emphasizes comprehensive...
3 min read
James K. Min, MD, FACC, FESC, MSCCT, Founder & CEO of Cleerly: September 19, 2022
Myocardial perfusion, also known as a "stress test", is today's go-to-method for detecting coronary artery disease - despite limited performance.
